Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 12/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045245 | 0.72 | FDPS (0.46) | FDPSGGPS1LMNAADRB3PDE4D | |
| SCHEMBL9706730 | 0.71 | MMP1 (0.33) | — | |
| SCHEMBL140140 | 0.67 | FDPS (0.39) | FDPS | |
| SCHEMBL10606739 | 0.64 | FDPS (0.46) | FDPSGGPS1LMNAADRB3PDE4D | |
| SCHEMBL370583 | 0.64 | FDPS (0.62) | FDPSGGPS1LMNAADRB3PDE4D | |
| SCHEMBL7151614 | 0.63 | MMP1 (0.30) | — | |
| SCHEMBL5196814 | 0.62 | FDPS (0.59) | FDPSGGPS1LMNAADRB3PDE4D | |
| SCHEMBL5586194 | 0.61 | LPAR3 (0.47) | FDPS | |
| SCHEMBL10875675 | 0.61 | LMNA (0.33) | FDPSLMNA | |
| SCHEMBL22644185 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233770-B1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2008-02-13 | — | — | EP | claimed |
| US-10071110-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| US-8710030-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140045794-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-20060281706-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-12-14 | — | — | US | disclosed |
| US-7098197-B2 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-29 | — | — | US | disclosed |
| US-7094772-B2 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-22 | — | — | US | disclosed |
| US-7034014-B2 | New derivatives of cidofovir, adefovir, cyclic cidofovir or tenofovir made by forming phosphonate ester with an alcohol such as alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol; e.g. 1-O-octadecylpropanediol-3-cidofovir; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-18 | — | — | US | disclosed |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-11 | — | — | US | disclosed |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-6716825-B2 | OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-06 | — | — | US | disclosed |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1089761-B1 | MEDICAMENTS CONTAINING BISPHOSPHONIC ACIDS AND DERIVATIVES THEREOF WHICH ARE PROVIDED FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES AND ALLERGIES | JOMAA HASSAN (DE) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045794-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | FDPS 115/4885GGPS1 91/4885LMNA 2747/4885 |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | ENPP1, ADA, ENTPD5 | FDPS 1302/4885GGPS1 151/4885LMNA 2121/4885 |
| US-10071110-B2 | Phosphonate compounds | PHPT1, PHOSPHO1, PIK3CA | FDPS 115/4885GGPS1 91/4885LMNA 2747/4885 |
| US-20060281706-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | FDPS 251/4885GGPS1 199/4885LMNA 3566/4885 |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | FDPS 251/4885GGPS1 199/4885LMNA 3566/4885 |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | BPGM, PPA1, INPP5D | FDPS 360/4885GGPS1 144/4885LMNA 3308/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | FDPS 115/4885GGPS1 91/4885LMNA 2747/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | FDPS 115/4885GGPS1 91/4885LMNA 2747/4885 |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | MTAP, SAMHD1, NT5C3B | FDPS 1276/4885GGPS1 264/4885LMNA 1745/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FDPS 506/4885GGPS1 991/4885LMNA 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.